[Indications for infliximab. How long should treatment last? Risk/benefit evaluation].
Eugenio
E
Domènech Morral
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000209:etiology; D003093:Colitis, Ulcerative / Q000628:therapy; D000075202:Contraindications; D003424:Crohn Disease / Q000628:therapy*; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000209:etiology; D006333:Heart Failure / Q000209:etiology; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D007157:Immunologic Surveillance / Q000187:drug effects; D007239:Infections / Q000209:etiology; D000069285:Infliximab; D007262:Infusions, Intravenous; D008223:Lymphoma / Q000209:etiology; D018570:Risk Assessment; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab